Direct-to-Consumer (DTC) Genetic Testing Market Report 2026

The direct-to-consumer (dtc) genetic testing market size has grown rapidly in recent years. It will grow from $2.14 billion in 2025 to $2.48 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to declining cost of dna sequencing, early ancestry testing adoption, increased health awareness, e-commerce penetration, consumer curiosity about genetics.

The direct-to-consumer (dtc) genetic testing market size is expected to see rapid growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to ai-driven genetic interpretation, expansion of precision medicine, regulatory frameworks for genetic data, integration with wellness platforms, demand for personalized healthcare. Major trends in the forecast period include rising consumer interest in genetic health insights, growth of ancestry and relationship testing, expansion of nutrigenomic and lifestyle testing, increasing use of online genetic test platforms, greater focus on personalized health risk assessment.

The rising prevalence of diseases and disorders with genetic transmission potential is expected to drive the growth of the direct-to-consumer (DTC) genetic testing market going forward. Genetic disorders are conditions caused by changes or mutations in an individual’s DNA and include single-gene, multifactorial, and chromosomal disorders. Direct-to-consumer genetic testing increases awareness of inherited conditions by offering insights into health risks, disease predisposition, and individual traits, enabling people to make informed health and lifestyle choices to reduce potential risks. For instance, in April 2023, the National Library of Medicine (NLM), a US-based medical library, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, a condition with a strong genetic component. This number is projected to rise to 13.8 million by 2060 in the absence of major medical breakthroughs. Therefore, the growing prevalence of genetically linked diseases and disorders is driving the expansion of the direct-to-consumer genetic testing market.

Major companies operating in the direct-to-consumer (DTC) genetic testing market are focusing on developing advanced offerings such as whole-genome sequencing (WGS) subscription platforms to deliver comprehensive genetic insights, enable personalized health planning, and improve long-term consumer engagement. WGS subscription platforms involve sequencing nearly the entire genome, allowing detailed analysis of ancestry, disease risk, wellness traits, and pharmacogenomics, far beyond the limited scope of traditional SNP-based testing. For instance, in November 2024, ProPhase Labs, a US-based biotechnology and diagnostics company, launched DNA Complete, a standalone direct-to-consumer WGS service under its subsidiary DNA Complete, Inc. The platform provides near-complete genome sequencing, tiered subscription plans including Essential, Pro, and Elite options, continuous result updates, and access to genetic counseling to assist users in understanding their data. The service combines advanced bioinformatics, ancestry analysis, and flexible sample processing through ProPhase’s Nebula Genomics laboratory or partner facilities, offering deep genomic insights with improved accessibility and ongoing engagement.

In July 2025, TTAM Research Institute, a US-based nonprofit public benefit corporation focused on advancing medical and genomic research, acquired substantially all assets of 23andMe Holding Co. for approximately $305 million. Through this acquisition, TTAM Research Institute gains access to 23andMe’s Personal Genome Service, research services operations, and its telehealth subsidiary, Lemonaid Health. This move strengthens TTAM’s capabilities in consumer-focused genetic testing, large-scale genomic data analysis, and research infrastructure, while expanding its reach in personalized health and wellness insights. 23andMe Holding Co. is a US-based consumer genomics company known for its at-home DNA testing kits and genetic insights related to ancestry, health risks, traits, and wellness.

Major companies operating in the direct-to-consumer (dtc) genetic testing market are 23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA, Living DNA, Vitagene, Orig3n, DNAfit, Helix, Color Genomics, Circle DNA, CRI Genetics, MapMyGenome, Invitae Corporation, TellmeGen, Pathway Genomics, Genebase Systems, EasyDNA, Nebula Genomics, Dante Labs, Veritas Genetics, Xcode Life, Genomic Express, Genomelink, Genomind, WellnessFX, LetsGetChecked, iGene, Dnadoc, OneOme.

North America was the largest region in the direct-to-consumer (DTC) genetic testing market share in 2025. Asia-Pacific was the second-largest region in the global direct-to-consumer (DTC) genetic testing market. The regions covered in the direct-to-consumer (dtc) genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the direct-to-consumer (dtc) genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the direct-to-consumer genetic testing market by increasing costs of imported sequencing equipment, reagents, and laboratory consumables. North America and Europe are most affected due to reliance on advanced imported technologies, while Asia-Pacific faces higher testing kit production costs. These tariffs raise consumer prices. However, they also encourage domestic genomics infrastructure and local testing capabilities.

The direct-to-consumer (dtc) genetic testing market research report is one of a series of new reports that provides direct-to-consumer (dtc) genetic testing market statistics, including direct-to-consumer (dtc) genetic testing industry global market size, regional shares, competitors with a direct-to-consumer (dtc) genetic testing market share, detailed direct-to-consumer (dtc) genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the direct-to-consumer (dtc) genetic testing industry. This direct-to-consumer (dtc) genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Direct-to-consumer genetic testing refers to the promotion and sale of genetic tests directly to individuals through channels such as television, radio, print media, and the internet. Consumers can purchase these test kits via online platforms or pharmacies, submit a DNA sample to the company, and access their genetic information through secure websites, mobile applications, or written reports, typically without the involvement of healthcare professionals or health insurance providers.

The main types of direct-to-consumer genetic testing include carrier testing, predictive testing, ancestry and relationship testing, nutrigenomic testing, and other test types. Carrier testing is a genetic screening method used to determine whether an individual carries a gene mutation associated with a specific inherited disorder. These tests analyze samples such as saliva, urine, and blood using technologies including single nucleotide polymorphism (SNP) chips, whole genome sequencing, and targeted analysis. They are offered through various business models, such as health planning models, comprehensive genome testing models, medical precision testing models, and restricted trait testing models, and are utilized by a wide range of end users, including laboratories, blood banks, nursing homes, hospitals, imaging centers, home care providers, cosmetic companies, and others.

The direct-to-consumer (DTC) genetic testing market includes revenues earned by entities by offering DTC genetic kits and services straight to end-customers, that are used in querying patients' DNA information. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.